New hope for advanced hodgkin lymphoma: drug combo trial launches
NCT ID NCT05949931
First seen May 13, 2026 · Last updated Jun 12, 2026 · Updated 4 times
Summary
This study tests whether adding pianzumab to standard chemotherapy (AVD) helps more people with newly-diagnosed advanced classic Hodgkin lymphoma achieve remission. About 108 adults with stage III-IV or high-risk stage IIB disease will participate. The goal is to see if the combination is safe and improves complete response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Conditions
Explore the condition pages connected to this study.